The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis

被引:117
作者
Chakraborty, Goutam [1 ]
Jain, Shalini [1 ]
Behera, Reeti [1 ]
Ahmed, Mansoor [1 ]
Sharma, Priyanka [1 ]
Kumar, Vinit [1 ]
Kundu, Gopal C. [1 ]
机构
[1] Natl Ctr Cell Sci, NCCS Complex, Pune 411007, Maharashtra, India
关键词
osteopontin; cell signaling; tumor progression; metastasis; angiogenesis;
D O I
10.2174/156652406779010803
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Osteopontin (OPN) is a chemokine like phosphorylated glycoprotein that plays important role in cancer progression. Extensive research from various laborities has demonstrated the likely role of OPN in regulating the cell signaling that ultimately controls tumor growth and metastasis. Several earlier reports indicated that OPN is associated with various cancers; but its functional role in carcinogenesis is still not well defined. Besides the role of OPN in tumor biology, several studies have demonstrated the pathophysiological role of OPN in diverse biological events. This review will focus on recent advances in understanding the molecular mechanism by which OPN regulates a series of signaling cascades through activation of various kinases and transcription factors that ultimately control the expression of downstream effector genes, which contribute to tumor progression and angiogenesis in vitro and animal models. We will also provide evidences that suggest the enhanced expression of OPN is not only associated with several tumor types, but its level of expression is directly correlated to various stages of the clinical specimans of breast and prostate cancers. These studies may be useful for identifying novel OPN-based therapeutic approuch for the treatment of cancer.
引用
收藏
页码:819 / 830
页数:12
相关论文
共 136 条
  • [1] Adwan H, 2004, INT J ONCOL, V24, P1235
  • [2] Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells
    Adwan, H
    Bäuerle, TJ
    Berger, MR
    [J]. CANCER GENE THERAPY, 2004, 11 (02) : 109 - 120
  • [3] Agrawal D, 2002, J NATL CANCER I, V94, P513
  • [4] Osteopontin identified as colon cancer tumor progression marker
    Agrawal, D
    Chen, T
    Irby, R
    Quackenbush, J
    Chambers, AF
    Szabo, M
    Cantor, A
    Coppola, D
    Yeatman, TJ
    [J]. COMPTES RENDUS BIOLOGIES, 2003, 326 (10-11) : 1041 - 1043
  • [5] Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activators
    Angelucci, A
    Festuccia, C
    D'Andrea, G
    Teti, A
    Bologna, M
    [J]. BIOLOGICAL CHEMISTRY, 2002, 383 (01) : 229 - 234
  • [6] Aprikian AG, 1997, INT J CANCER, V72, P498, DOI 10.1002/(SICI)1097-0215(19970729)72:3<498::AID-IJC19>3.3.CO
  • [7] 2-P
  • [8] Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity
    Ashkar, S
    Weber, GF
    Panoutsakopoulou, V
    Sanchirico, ME
    Jansson, M
    Zawaideh, S
    Rittling, SR
    Denhardt, DT
    Glimcher, MJ
    Cantor, H
    [J]. SCIENCE, 2000, 287 (5454) : 860 - 864
  • [9] Atkins K, 1998, J CELL PHYSIOL, V175, P229, DOI 10.1002/(SICI)1097-4652(199805)175:2<229::AID-JCP13>3.0.CO
  • [10] 2-3